d-Lenolate® 60-ct 500mg

It is formulated based on a patented extraction process of carefully selected and analyzed olive leaves that contain Oleuropein and other therapeutic compound found in olive leaves.The product has been proven and demonstrated considerable therapeutic action against health problems, through scientific research and studies.

For more than 15 years, d-Lenolate has helped thousands of customers improve the function of their immune systems. This supplement has been, and continues to be, tested by both U.S. and international university research teams, with results proving it to be one of the best, natural and most effective way to strengthen the immune system.

Although d-Lenolate is the core sales product, East Park Research manufactures and distributes a line of products that utilizes the d-Lenolate formulation as its key ingredient. The product mix contains a topical formula, cleansing bar, shampoo, conditioner, Flu-Ban, and many others.

Summary of research and studies

Antimicrobial Activities of d-Lenolate:

Recent research at University of Nevada Las Vegas (UNLV) has revealed d-Lenolate demonstrates effective direct anti-microbial activity against representatives of both Gram positive and Gram negative bacteria. Expanded research also showed d-Lenolate is effective in inhibiting growth of several hospital-based pathogens.

Microbial Infections:

d-Lenolate was evaluated as a protective agent against two bacterial species in mice: E.coli, Pseudomonas aeruginosa and the yeast, Candida albicans. d-Lenolate enhanced the restoration of white blood cells to the normal level and protected against infection with bacteria and yeast. In this study, d-lenolate restored PMN levels in the immuno-compromised mice and also enhanced clearance of E.coli from blood, both restorative effects after infection with bacteria. These two factors make d-Lenolate a powerful protectant from infection as well as an enhancer to recovery post infection. d-Lenolate was able to restore immune function after treatment with all of these agents.

In this study conducted by the Japanese scientist, d-Lenolate was able to restore antibody production after chemotherapy. Therefore, d-Lenolate functions in the early stages of infection by enhancing PMN number and function antibody production capability of B cells. All of these d-Lenolate-induced functions make the efficacy of cellular mechanisms in late stage influenza virus infection more successful when the immune system is depressed and at least equivalent to healthy mice responses.

Influenza and extra cellular bacterial infection:

Two “animal” studies, performed by a very prominent Japanese research organization, focuses on the effects of d-Lenolate on the body’s immune system and how the enhanced immune system destroys viruses and bacteria. d-Lenolate appears to be successful remedy for influenza and extra cellular bacterial infection. It is particularly useful as preventative treatment prior to exposure and as a support to enhance healing in exposed and immuno-compromised mice.

Candida:

In January 1999, Dr. Bernard Mizock evaluated d-Lenolate in the control of symptoms of Candida Hypersensitivity Syndrome. It was concluded at the end of the double-blind study that d-Lenolate reduced the symptoms of chronic yeast infections by greater than 50% within 60 days of its use with no apparent side effects. Continued use may be warranted to enhance an ongoing treatment protocol.

Arthritis:

d-Lenolate was again used by Dr. Mizock in a second study to record the modifications of symptoms related to arthritic symptoms. Using the Western Ontario and McMaster Universities Arthrities (WOMAC) index, scores were obtained during the period of September 2000 to January 2001 at baseline, 20,40, and 60 days. Dr. Mizock concluded that d-Lenolate improves the symptoms of arthritis. The effects were first noted at 20 days, and reach a maximum effect of 32% improvement at 40 days.

Herpes Simplex I:

Recently, East Park Research, in a coordinated effort with one of the research Universities has been testing its Topical for the past two years on various skin conditions to determine its efficacy in scientific clinical environment. It was shown at the conclusion of the first phase of testing the d-Lenolate has a direct causal effect on cold sores, also known as Herpes Simplex I. It was also shown to assist in the healing of human tissue having the herpes symptoms present. The inhibition of spreading is one of the very exciting properties of this final formulation, now called Deleve cream, a new addition to East Park Research products.

Deleve was evaluated for its safety in animals with no toxic effects observed. The treated skin remained clear of inflammation and redness and all animals appeared normal throughout the duration of the study.

West Nile Virus:

d-Lenolate was also evaluated for its activities against anti-West Nile Virus (WNV) and showed an 80% reduction in viral plaque numbers at higher concentration of d-Lenolate.